Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Woodward ND, Purdon SE, Meltzer HY, Zald DH.

Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72. Epub 2005 Mar 23. Review.

PMID:
15784157
2.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators..

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
3.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
4.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
5.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
6.

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

Meltzer HY, McGurk SR.

Schizophr Bull. 1999;25(2):233-55. Review.

PMID:
10416729
7.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators.; Neurocognitive Working Group..

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
8.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA.

Am J Psychiatry. 2007 Jul;164(7):1061-71.

10.

Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A.

Schizophr Res. 2015 Feb;161(2-3):429-33. doi: 10.1016/j.schres.2014.12.024. Epub 2014 Dec 30.

12.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
13.
14.

Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.

Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.

Am J Psychiatry. 2004 Sep;161(9):1620-5.

PMID:
15337652
15.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
16.

A model of anticholinergic activity of atypical antipsychotic medications.

Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G.

Schizophr Res. 2006 Dec;88(1-3):63-72. Epub 2006 Aug 22.

PMID:
16928430
17.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
18.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
19.

Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.

Han M, Zhang XY, Chen DC, Tan YL, Song CS, Yu YH, Huang XF.

Int Clin Psychopharmacol. 2015 Mar;30(2):89-95. doi: 10.1097/YIC.0000000000000066.

PMID:
25568968
20.

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.

Torrent C, Martinez-Arán A, Daban C, Amann B, Balanzá-Martínez V, del Mar Bonnín C, Cruz N, Franco C, Tabarés-Seisdedos R, Vieta E.

Compr Psychiatry. 2011 Nov-Dec;52(6):613-22. doi: 10.1016/j.comppsych.2010.12.009. Epub 2011 Feb 4.

PMID:
21295774

Supplemental Content

Support Center